Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)

Table 5 Univariate and multivariate analysis of RFS and OS including the most important clinicopathologic parameters

Variable	RFS			Multivariate			OS			Multivariate
	Univariate			Multivariate			Univariate			Multivariate
	P value*	HR	95% CI	P value*	HR	95% CI	P value*	HR	95% CI	P value*	HR	95% CI
pCR	0.003	3.77	1.49–9.51	0.033	2.91	1.09–7.78	0.003	11.32	1.54–88.34	0.043	8.29	1.07–64.00
rCR	< 0.001	3.26	1.62–6.55	0.037	2.17	1.05–4.48	< 0.001	6.70	2.02–22.20	0.033	3.78	1.11–12.87
AJCC stage	0.001	0.33	0.17–0.64	0.004	0.37	0.19–0.73	0.016	0.35	0.15–0.82	0.076	0.45	0.19–1.09
Grading	0.635	0.87	0.49–1.55				0.432	0.74	0.35–1.58
Ki-67	0.909	1.05	0.47–2.32				0.366	1.75	0.51–6.03
HR status	0.029	1.90	1.06–3.41	< 0.001	2.99	1.64–5.47	0.003	3.33	1.41–7.83	< 0.001	5.33	2.24–12.66
HER2 status	0.652	1.16	0.61–2.19				0.073	2.55	0.88–7.34
Menopausal status	0.964	0.99	0.54–1.81				0.351	1.44	0.67–3.13

pCR pathologic complete response, rCR radiologic complete response, AJJC American Joint Committee on Cancer, RFS recurrence-free survival, OS overall survival, HR hormone receptor, HER2 human epidermal growth factor receptor 2
*Log rank test (Mantel-Cox)

ISSN: 1465-542X